JP2017504601A - 免疫療法のためにマルチインプットシグナル感受性ｔ細胞を操作する方法 - Google Patents

免疫療法のためにマルチインプットシグナル感受性ｔ細胞を操作する方法 Download PDF

Info

Publication number
JP2017504601A
JP2017504601A JP2016541194A JP2016541194A JP2017504601A JP 2017504601 A JP2017504601 A JP 2017504601A JP 2016541194 A JP2016541194 A JP 2016541194A JP 2016541194 A JP2016541194 A JP 2016541194A JP 2017504601 A JP2017504601 A JP 2017504601A
Authority
JP
Japan
Prior art keywords
domain
car
cells
cell
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016541194A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017504601A5 (enExample
Inventor
アレキサンドル ジュイラ
アレキサンドル ジュイラ
クラウディア ベルトナティ
クラウディア ベルトナティ
ジュリアン ヴァルトン
ジュリアン ヴァルトン
フィリップ デュシャトー
フィリップ デュシャトー
ローラン ポワロ
ローラン ポワロ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cellectis SA
Original Assignee
Cellectis SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellectis SA filed Critical Cellectis SA
Publication of JP2017504601A publication Critical patent/JP2017504601A/ja
Publication of JP2017504601A5 publication Critical patent/JP2017504601A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
JP2016541194A 2013-12-20 2014-12-19 免疫療法のためにマルチインプットシグナル感受性ｔ細胞を操作する方法 Pending JP2017504601A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201370806 2013-12-20
DKPA201370806 2013-12-20
PCT/EP2014/078876 WO2015092024A2 (en) 2013-12-20 2014-12-19 Method of engineering multi-input signal sensitive t cell for immunotherapy

Publications (2)

Publication Number Publication Date
JP2017504601A true JP2017504601A (ja) 2017-02-09
JP2017504601A5 JP2017504601A5 (enExample) 2018-01-18

Family

ID=49884853

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016541194A Pending JP2017504601A (ja) 2013-12-20 2014-12-19 免疫療法のためにマルチインプットシグナル感受性ｔ細胞を操作する方法

Country Status (6)

Country Link
US (1) US10239948B2 (enExample)
EP (2) EP3808410A1 (enExample)
JP (1) JP2017504601A (enExample)
AU (1) AU2014368383B2 (enExample)
CA (1) CA2934436A1 (enExample)
WO (1) WO2015092024A2 (enExample)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020512019A (ja) * 2017-03-31 2020-04-23 セレクティス ソシエテ アノニム ユニバーサル抗ｃｄ２２キメラ抗原受容体操作免疫細胞
WO2020175366A1 (ja) * 2019-02-25 2020-09-03 国立大学法人東京医科歯科大学 キメラ抗原受容体
JPWO2021131944A1 (enExample) * 2019-12-27 2021-07-01
JP2022520285A (ja) * 2019-02-19 2022-03-29 キングス カレッジ ロンドン 低酸素応答性キメラ抗原受容体
JP2022533806A (ja) * 2018-11-06 2022-07-26 イミュニティーバイオ、インコーポレイテッド キメラ抗原受容体で修飾されたｎｋ－９２細胞
JP2024001096A (ja) * 2018-05-22 2024-01-09 イミュニティーバイオ、インコーポレイテッド ＦｃイプシロンＣＡＲ
US12109238B2 (en) 2018-11-06 2024-10-08 Immunitybio, Inc. Chimeric antigen receptor-modified NK-92 cells

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2694640B1 (en) 2011-04-08 2017-10-18 Baylor College Of Medicine Reversing the effects of the tumor microenvironment using chimeric cytokine receptors
US9745548B2 (en) 2012-03-15 2017-08-29 Flodesign Sonics, Inc. Acoustic perfusion devices
US10322949B2 (en) 2012-03-15 2019-06-18 Flodesign Sonics, Inc. Transducer and reflector configurations for an acoustophoretic device
US9752113B2 (en) 2012-03-15 2017-09-05 Flodesign Sonics, Inc. Acoustic perfusion devices
US9950282B2 (en) 2012-03-15 2018-04-24 Flodesign Sonics, Inc. Electronic configuration and control for acoustic standing wave generation
US10967298B2 (en) 2012-03-15 2021-04-06 Flodesign Sonics, Inc. Driver and control for variable impedence load
US10689609B2 (en) 2012-03-15 2020-06-23 Flodesign Sonics, Inc. Acoustic bioreactor processes
US9458450B2 (en) 2012-03-15 2016-10-04 Flodesign Sonics, Inc. Acoustophoretic separation technology using multi-dimensional standing waves
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
US10737953B2 (en) 2012-04-20 2020-08-11 Flodesign Sonics, Inc. Acoustophoretic method for use in bioreactors
SG11201505858VA (en) 2013-01-28 2015-09-29 St Jude Childrens Res Hospital A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease
US9745569B2 (en) 2013-09-13 2017-08-29 Flodesign Sonics, Inc. System for generating high concentration factors for low cell density suspensions
CN105939767B (zh) 2014-01-08 2018-04-06 弗洛设计声能学公司 具有双声电泳腔的声电泳装置
TR201910814T4 (tr) 2014-03-19 2019-08-21 Cellectis Kanser immünoterapisi için cd123 spesifik kimerik antijen reseptörleri.
SG10201808811QA (en) 2014-04-10 2018-11-29 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Method and compositions for cellular immunotherapy
EP3131927B8 (en) 2014-04-14 2020-12-23 Cellectis Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy
EP3805371A1 (en) 2014-05-15 2021-04-14 National University of Singapore Modified natural killer cells and uses thereof
US9744483B2 (en) 2014-07-02 2017-08-29 Flodesign Sonics, Inc. Large scale acoustic separation device
TWI751102B (zh) 2014-08-28 2022-01-01 美商奇諾治療有限公司 對ｃｄ１９具專一性之抗體及嵌合抗原受體
HRP20240357T1 (hr) 2014-12-24 2024-06-07 Autolus Limited Stanica
EP3250602A1 (en) 2015-01-26 2017-12-06 Cellectis T cell receptor knock out engineered immune cells, endowed with chimeric antigen receptors binding to cd123 for the treatment of relapsed/refractory acute myeloid lymphoma or blastic plasmacytoid dendritic cell neoplasm
WO2016126608A1 (en) * 2015-02-02 2016-08-11 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
PL3280729T3 (pl) 2015-04-08 2022-08-22 Novartis Ag Terapie cd20, terapie cd22 i terapie skojarzone komórką eksprymującą chimeryczny receptor antygenowy (car) cd19
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11021699B2 (en) 2015-04-29 2021-06-01 FioDesign Sonics, Inc. Separation using angled acoustic waves
EP3770168A1 (en) 2015-05-18 2021-01-27 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
WO2017008019A1 (en) * 2015-07-08 2017-01-12 The Johns Hopkins University Marrow infiltrating lymphocytes (mils) as a source of t-cells for chimeric antigen receptor (car) therapy
US11474085B2 (en) 2015-07-28 2022-10-18 Flodesign Sonics, Inc. Expanded bed affinity selection
US11459540B2 (en) 2015-07-28 2022-10-04 Flodesign Sonics, Inc. Expanded bed affinity selection
CA2992797A1 (en) 2015-08-03 2017-02-09 Engmab Sarl Monoclonal antibodies against bcma
MX2018001568A (es) 2015-08-07 2019-04-25 Seattle Children´S Hospital Dba Seattle Children´S Res Institute Celulas t biespecificas de receptor quimerico de antigeno (car) para focalizacion a tumores solidos.
JP7012645B2 (ja) * 2016-01-11 2022-01-28 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー キメラタンパク質および免疫治療の方法
WO2017123559A2 (en) * 2016-01-11 2017-07-20 The Board Of Trustees Of The Leland Stanford Junior University Chimeric proteins and methods of regulating gene expression
BR112018014585A2 (pt) * 2016-01-21 2018-12-11 Pfizer receptores de antígeno quiméricos que direcionam o receptor do fator de crescimento epidérmico variante iii
ES2904593T3 (es) 2016-01-21 2022-04-05 Pfizer Anticuerpos monoespecíficos y biespecíficos para la variante III del receptor del factor de crecimiento epidérmico y CD3 y sus usos
EP3202783A1 (en) 2016-02-02 2017-08-09 Ecole Polytechnique Fédérale de Lausanne (EPFL) Engineered antigen presenting cells and uses thereof
WO2017144630A1 (en) * 2016-02-26 2017-08-31 Cellectis Micelle based system nuclease encapsulation for in-vivo gene editing
CN107298715B (zh) * 2016-04-15 2021-05-04 阿思科力(苏州)生物科技有限公司 Slit2D2-嵌合抗原受体及其应用
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
US11085035B2 (en) 2016-05-03 2021-08-10 Flodesign Sonics, Inc. Therapeutic cell washing, concentration, and separation utilizing acoustophoresis
GB201609604D0 (en) * 2016-06-01 2016-07-13 Ucl Business Plc Cell
KR20190019121A (ko) * 2016-06-17 2019-02-26 오사카 유니버시티 종양 내 정맥 형성 촉진제
WO2018026953A1 (en) 2016-08-02 2018-02-08 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
WO2018058432A1 (zh) * 2016-09-28 2018-04-05 李华顺 一种多基因重组嵌合抗原受体分子及其应用
BR112019007100A2 (pt) 2016-10-07 2019-06-25 Tcr2 Therapeutics Inc composições e métodos para reprogramação de receptores de célula t com o uso de proteínas de fusão
EP3529347A1 (en) 2016-10-19 2019-08-28 Flodesign Sonics, Inc. Affinity cell extraction by acoustics
WO2018073393A2 (en) 2016-10-19 2018-04-26 Cellectis Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy
US11124577B2 (en) 2016-11-02 2021-09-21 Engmab Sàrl Bispecific antibody against BCMA and CD3 and an immunological drug for combined use in treating multiple myeloma
CN110177803A (zh) 2016-11-22 2019-08-27 T细胞受体治疗公司 用于使用融合蛋白进行tcr重新编程的组合物和方法
WO2018111763A1 (en) 2016-12-12 2018-06-21 Seattle Children's Hospital (dba Seattle Children's Research Institute) Chimeric transcription factor variants with augmented sensitivity to drug ligand induction of transgene expression in mammalian cells
CN117363636A (zh) 2017-03-27 2024-01-09 新加坡国立大学 一种编码嵌合受体的多核苷酸
MX2019011570A (es) 2017-03-27 2019-11-18 Nat Univ Singapore Lineas celulares estimuladoras para expansion y activacion ex vivo de celulas asesinas naturales.
WO2018193231A1 (en) * 2017-04-18 2018-10-25 Autolus Limited Cell
CA3063695A1 (en) * 2017-05-17 2018-11-22 Seattle Children's Hospital (Dba Seattle Children's Research Institute Generating mammalian t cell activation inducible synthetic promoters (syn+pro) to improve t cell therapy
AU2018292181B2 (en) 2017-06-30 2025-04-10 Cellectis Cellular immunotherapy for repetitive administration
GB201711470D0 (en) * 2017-07-17 2017-08-30 Univ Oxford Innovation Ltd Chimeric receptors
WO2019025800A1 (en) * 2017-08-02 2019-02-07 Autolus Limited CELLS EXPRESSING A CHIMERIC ANTIGENIC RECEPTOR OR A MANIPULATED TCR AND COMPRISING A SELECTIVELY EXPRESSED SELECTIVE NUCLEOTIDE SEQUENCE
WO2019072824A1 (en) 2017-10-09 2019-04-18 Cellectis IMPROVED ANTI-CD123 CAR IN UNIVERSAL MODIFIED IMMUNE T LYMPHOCYTES
CN114900773A (zh) 2017-12-14 2022-08-12 弗洛设计声能学公司 声泳系统及其操作方法、控制声换能器及声学系统的方法
EP3723774A4 (en) 2017-12-15 2021-09-08 The Board of Trustees of the Leland Stanford Junior University COMPOSITIONS AND METHODS OF INHIBITION OF T-CELL EXHAUSTATION
JP7360174B2 (ja) 2018-02-09 2023-10-12 ナショナル ユニヴァーシティー オブ シンガポール ナチュラルキラー細胞免疫療法における活性化キメラ受容体及びその使用
US12441787B2 (en) 2018-04-02 2025-10-14 National University Of Singapore Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells
CA3096202A1 (en) 2018-04-06 2019-10-10 The Regents Of The University Of California Methods of treating egfrviii expressing glioblastomas
EP3773633A4 (en) 2018-04-06 2022-01-26 The Regents of The University of California METHODS OF TREATMENT OF GLIOBLASTOMA
WO2020028744A1 (en) * 2018-08-02 2020-02-06 Asimov, Inc. Universal chimeric receptors
AU2019317278B2 (en) 2018-08-07 2025-05-22 Purdue Research Foundation Rejuvenation of CAR T cell
WO2020044239A1 (en) 2018-08-29 2020-03-05 National University Of Singapore A method to specifically stimulate survival and expansion of genetically-modified immune cells
EP3844499A1 (en) * 2018-08-31 2021-07-07 Invectys Sa Method to assess car functionality
US11542305B2 (en) * 2018-08-31 2023-01-03 California Institute Of Technology Synthetic protein circuits detecting signal transducer activity
EP3850088A4 (en) 2018-09-07 2023-07-19 Beam Therapeutics, Inc. Compositions and methods for improving base editing
KR20210055733A (ko) 2018-09-07 2021-05-17 빔 테라퓨틱스, 인크. 핵염기 편집 시스템을 전달하기 위한 조성물 및 방법
CN119569895A (zh) 2018-11-01 2025-03-07 朱诺治疗学股份有限公司 G蛋白偶合受体c类5族成员d(gprc5d)特异性嵌合抗原受体
US12466892B2 (en) 2018-11-08 2025-11-11 The Regents Of The University Of California Systems and methods for targeting cancer cells
US20220000921A1 (en) * 2018-11-20 2022-01-06 Innovative Cellular Therapeutics Holdings, Ltd. Modified Cell Expressing Therapeutic Agent and Uses thereof
CN113226340A (zh) 2018-11-26 2021-08-06 恩卡尔塔公司 同时扩增多种免疫细胞类型的方法、相关组合物及其在癌症免疫疗法中的用途
JP7646552B2 (ja) 2019-01-31 2025-03-17 ビーム セラピューティクス インク． 低減された非標的脱アミノ化を有する核酸塩基エディターおよび核酸塩基エディターの特徴づけのためのアッセイ
US12600971B2 (en) 2019-02-13 2026-04-14 Beam Therapeutics Inc. Modified immune cells having adenosine deaminase base editors for modifying a nucleobase in a target sequence
WO2020168135A1 (en) 2019-02-13 2020-08-20 Beam Therapeutics Inc. Compositions and methods for treating alpha-1 antitrypsin deficiency
KR20210137085A (ko) 2019-03-05 2021-11-17 엔카르타, 인크. Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도
WO2020219843A1 (en) * 2019-04-26 2020-10-29 The University Of North Carolina At Chapel Hill Chimeric antigen receptor constructs and their use in car-t cells
US12594301B2 (en) 2019-09-27 2026-04-07 Beam Therapeutics Inc. Compositions and methods for treatment of liquid cancers
JP7805928B2 (ja) 2019-11-26 2026-01-26 ノバルティス アーゲー Ｃｄ１９及びｃｄ２２キメラ抗原受容体及びその使用
MX2022007107A (es) * 2019-12-11 2022-11-14 Myeloid Therapeutics Inc Composiciones celulares terapeuticas y metodos de preparacion y usos de las mismas.
WO2022046755A1 (en) * 2020-08-28 2022-03-03 Innovative Cellular Therapeutics Holdings, Ltd. Fusion protein enhancing cell therapy
CN116635044A (zh) * 2020-08-28 2023-08-22 创新细胞治疗控股有限公司 融合蛋白增强细胞疗法
AU2021347359A1 (en) 2020-09-25 2023-05-18 Beam Therapeutics Inc. Fratricide resistant modified immune cells and methods of using the same
TW202241935A (zh) 2020-12-18 2022-11-01 美商世紀治療股份有限公司 具有可調適受體專一性之嵌合抗原受體系統
MX2024003887A (es) 2021-10-14 2024-07-09 Arsenal Biosciences Inc Células inmunitarias que tienen arnch coespresados y sistemas de compuerta lógica.
US20250319126A1 (en) * 2021-10-29 2025-10-16 Shanghai Sinobay Biotechnology Co., Ltd. Condition-controlled spliceable chimeric antigen receptor molecule and application thereof
US20250017960A1 (en) * 2021-11-15 2025-01-16 The Board Of Trustees Of The Leland Stanford Junior University Composition and method of valency controlled receptor systems for cell engineering and therapy
WO2024015383A1 (en) * 2022-07-12 2024-01-18 Northwestern University Engineered hypoxia biosensors and methods of using the same
EP4565262A2 (en) 2022-08-05 2025-06-11 Juno Therapeutics, Inc. Chimeric antigen receptors specific for gprc5d and bcma
AU2023325029A1 (en) * 2022-08-15 2025-03-06 The Regents Of The University Of California Multi-chain synthetic receptors for simultaneous ligand‑induced transcriptional regulation and membrane‑proximal signal transduction
KR20250084940A (ko) 2022-09-30 2025-06-11 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 입양 t 세포 치료를 향상시키기 위한 조성물 및 방법
CN119306846A (zh) * 2023-07-14 2025-01-14 广州百吉生物制药有限公司 一种工程化免疫细胞及其制备和应用
WO2025054489A1 (en) * 2023-09-08 2025-03-13 The Regents Of The University Of California Chimeric antigen receptors with card domains
CN122206449A (zh) * 2023-10-05 2026-06-12 加利福尼亚大学董事会 Card11-pik3r3融合蛋白的调节的表达
WO2025084881A1 (ko) * 2023-10-20 2025-04-24 주식회사 이온셀 Ct83 항원에 결합하는 car-t 세포 및 이의 용도

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004524848A (ja) * 2001-03-21 2004-08-19 アイシス イノヴェイション リミテッド アッセイ、方法および手段
JP2008509209A (ja) * 2004-08-09 2008-03-27 キャンサー・リサーチ・テクノロジー・リミテッド αケトグルタレート類および治療薬としてのその使用
JP2009545310A (ja) * 2006-07-31 2009-12-24 ヴァスキュラー バイオジェニックス リミテッド ポリペプチド、および、当該ポリペプチドをコードするポリヌクレオチド、および、虚血に関連する医学的状態の治療におけるそれらの使用
WO2012099973A2 (en) * 2011-01-18 2012-07-26 The Trustees Of The University Of Pennsylvania Compositions and methods for treating cancer
WO2013176916A1 (en) * 2012-05-25 2013-11-28 Roman Galetto Use of pre t alpha or functional variant thereof for expanding tcr alpha deficient t cells
WO2014153270A1 (en) * 2013-03-16 2014-09-25 Novartis Ag Treatment of cancer using humanized anti-cd19 chimeric antigen receptor
WO2014180306A1 (zh) * 2013-05-08 2014-11-13 上海益杰生物技术有限公司 编码gpc3嵌合抗原受体蛋白的核酸及表达gpc3嵌合抗原受体蛋白的t淋巴细胞
WO2014184741A1 (en) * 2013-05-13 2014-11-20 Cellectis Methods for engineering allogeneic and highly active t cell for immunotheraphy
WO2014184744A1 (en) * 2013-05-13 2014-11-20 Cellectis Methods for engineering highly active t cell for immunotherapy
WO2014184143A1 (en) * 2013-05-13 2014-11-20 Cellectis Cd19 specific chimeric antigen receptor and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8611832D0 (en) 1986-05-15 1986-06-25 Holland I B Polypeptide
US5037743A (en) 1988-08-05 1991-08-06 Zymogenetics, Inc. BAR1 secretion signal
PT1853718E (pt) * 2005-02-15 2015-11-12 Univ Duke Anticorpos anti-cd19 e usos em oncologia
WO2009023386A2 (en) * 2007-07-06 2009-02-19 Trubion Pharmaceuticals, Inc. Binding peptides having a c-terminally disposed specific binding domain
CA2735456C (en) * 2008-08-26 2021-11-16 City Of Hope Method and compositions for enhanced anti-tumor effector functioning of t cells
PH12013501201A1 (en) * 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
JP6177780B2 (ja) 2011-09-28 2017-08-09 エラ、ビオテック、ソシエダッド、アノニマＥｒａ Ｂｉｏｔｅｃｈ， Ｓ．Ａ． スプリットインテインおよびその使用
EP2814846B1 (en) 2012-02-13 2020-01-08 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
US20130280220A1 (en) 2012-04-20 2013-10-24 Nabil Ahmed Chimeric antigen receptor for bispecific activation and targeting of t lymphocytes
CN103483452B (zh) * 2012-06-12 2021-08-13 上海细胞治疗集团有限公司 双信号独立的嵌合抗原受体及其用途
AU2013312838B2 (en) * 2012-09-04 2018-11-29 Cellectis Multi-chain chimeric antigen receptor and uses thereof
ES2769574T3 (es) * 2013-03-15 2020-06-26 Michael C Milone Reconocimiento de células citotóxicas con receptores quiméricos para inmunoterapia adoptiva
EP3027204B1 (en) * 2013-07-29 2022-01-05 2seventy bio, Inc. Multipartite signaling proteins and uses thereof

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004524848A (ja) * 2001-03-21 2004-08-19 アイシス イノヴェイション リミテッド アッセイ、方法および手段
JP2008509209A (ja) * 2004-08-09 2008-03-27 キャンサー・リサーチ・テクノロジー・リミテッド αケトグルタレート類および治療薬としてのその使用
JP2009545310A (ja) * 2006-07-31 2009-12-24 ヴァスキュラー バイオジェニックス リミテッド ポリペプチド、および、当該ポリペプチドをコードするポリヌクレオチド、および、虚血に関連する医学的状態の治療におけるそれらの使用
WO2012099973A2 (en) * 2011-01-18 2012-07-26 The Trustees Of The University Of Pennsylvania Compositions and methods for treating cancer
WO2013176916A1 (en) * 2012-05-25 2013-11-28 Roman Galetto Use of pre t alpha or functional variant thereof for expanding tcr alpha deficient t cells
WO2013176915A1 (en) * 2012-05-25 2013-11-28 Roman Galetto Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy
US20140134142A1 (en) * 2012-05-25 2014-05-15 Cellectis Multi-Chain Chimeric Antigen Receptor and Uses Thereof
WO2014153270A1 (en) * 2013-03-16 2014-09-25 Novartis Ag Treatment of cancer using humanized anti-cd19 chimeric antigen receptor
WO2014180306A1 (zh) * 2013-05-08 2014-11-13 上海益杰生物技术有限公司 编码gpc3嵌合抗原受体蛋白的核酸及表达gpc3嵌合抗原受体蛋白的t淋巴细胞
WO2014184741A1 (en) * 2013-05-13 2014-11-20 Cellectis Methods for engineering allogeneic and highly active t cell for immunotheraphy
WO2014184744A1 (en) * 2013-05-13 2014-11-20 Cellectis Methods for engineering highly active t cell for immunotherapy
WO2014184143A1 (en) * 2013-05-13 2014-11-20 Cellectis Cd19 specific chimeric antigen receptor and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ANG SONNY O; OLIVARES SIMON; DENIGER DREW C; LEE DEAN A; CHAMPLIN RICHARD E; COOPER LAURENCE J: "CONDITIONAL ACTIVATION OF T CELLS TO SPECIFICALLY TARGET C-MET UNDER HYPOXIA", MOLECULAR THERAPY, vol. VOL:17, NR:SUPPL.1, JPN5017001555, May 2009 (2009-05-01), GB, pages 25 - 26, ISSN: 0004286322 *
ANG SONNY O; OLIVARES SIMON; SHPALL ELIZABETH J; LEE DEAN A; CHAMPLIN RICHARD, ET AL.: "CONDITIONAL T-CELL ACTIVATION FOR TUMOR UNDER HYPOXIA", BLOOD, vol. VOL:112, NR:11, JPN5017001556, November 2008 (2008-11-01), US, pages 1331 - 1332, ISSN: 0004286323 *
PLOS ONE, vol. 8(2), JPN6019029963, 2013, pages 57695 - 1, ISSN: 0004286324 *

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020512019A (ja) * 2017-03-31 2020-04-23 セレクティス ソシエテ アノニム ユニバーサル抗ｃｄ２２キメラ抗原受容体操作免疫細胞
JP7634045B2 (ja) 2017-03-31 2025-02-20 セレクティス ソシエテ アノニム ユニバーサル抗ｃｄ２２キメラ抗原受容体操作免疫細胞
JP2023139070A (ja) * 2017-03-31 2023-10-03 セレクティス ソシエテ アノニム ユニバーサル抗ｃｄ２２キメラ抗原受容体操作免疫細胞
JP7314115B2 (ja) 2017-03-31 2023-07-25 セレクティス ソシエテ アノニム ユニバーサル抗ｃｄ２２キメラ抗原受容体操作免疫細胞
JP2024001096A (ja) * 2018-05-22 2024-01-09 イミュニティーバイオ、インコーポレイテッド ＦｃイプシロンＣＡＲ
JP7748431B2 (ja) 2018-05-22 2025-10-02 イミュニティーバイオ、インコーポレイテッド ＦｃイプシロンＣＡＲ
US12435122B2 (en) 2018-05-22 2025-10-07 Immunitybio, Inc. Fc-epsilon CAR
JP7739389B2 (ja) 2018-11-06 2025-09-16 イミュニティーバイオ、インコーポレイテッド キメラ抗原受容体で修飾されたｎｋ－９２細胞
JP2022533806A (ja) * 2018-11-06 2022-07-26 イミュニティーバイオ、インコーポレイテッド キメラ抗原受容体で修飾されたｎｋ－９２細胞
JP2025186299A (ja) * 2018-11-06 2025-12-23 イミュニティーバイオ、インコーポレイテッド キメラ抗原受容体で修飾されたｎｋ－９２細胞
JP2024037752A (ja) * 2018-11-06 2024-03-19 イミュニティーバイオ、インコーポレイテッド キメラ抗原受容体で修飾されたｎｋ－９２細胞
JP7536649B2 (ja) 2018-11-06 2024-08-20 イミュニティーバイオ、インコーポレイテッド キメラ抗原受容体で修飾されたｎｋ－９２細胞
US12109238B2 (en) 2018-11-06 2024-10-08 Immunitybio, Inc. Chimeric antigen receptor-modified NK-92 cells
JP2022520285A (ja) * 2019-02-19 2022-03-29 キングス カレッジ ロンドン 低酸素応答性キメラ抗原受容体
JP7684692B2 (ja) 2019-02-19 2025-05-28 キングス カレッジ ロンドン 低酸素応答性キメラ抗原受容体
JP7684691B2 (ja) 2019-02-25 2025-05-28 国立大学法人東京科学大学 キメラ抗原受容体
JPWO2020175366A1 (enExample) * 2019-02-25 2020-09-03
WO2020175366A1 (ja) * 2019-02-25 2020-09-03 国立大学法人東京医科歯科大学 キメラ抗原受容体
JP7737708B2 (ja) 2019-12-27 2025-09-11 国立大学法人神戸大学 癌遺伝子治療薬
WO2021131944A1 (ja) * 2019-12-27 2021-07-01 国立大学法人神戸大学 癌遺伝子治療薬
JPWO2021131944A1 (enExample) * 2019-12-27 2021-07-01
US12459984B2 (en) 2019-12-27 2025-11-04 National University Corporation Kobe University Cancer gene therapy drug

Also Published As

Publication number Publication date
AU2014368383B2 (en) 2020-01-16
CA2934436A1 (en) 2015-06-25
AU2014368383A1 (en) 2016-06-30
EP3083691A2 (en) 2016-10-26
EP3808410A1 (en) 2021-04-21
US20170073423A1 (en) 2017-03-16
US10239948B2 (en) 2019-03-26
WO2015092024A3 (en) 2015-08-13
WO2015092024A2 (en) 2015-06-25

Similar Documents

Publication Publication Date Title
US10239948B2 (en) Method of engineering multi-input signal sensitive T cell for immunotherapy
AU2021201967B2 (en) Methods for engineering allogeneic and immunosuppressive resistant T cell for immunotherapy
JP6998917B2 (ja) 免疫療法のために同種異系かつ高活性のｔ細胞を操作するための方法
CN110869046B (zh) 通用型抗cd22嵌合抗原受体工程化的免疫细胞
AU2016313082B2 (en) Chimeric antigen receptors with integrated controllable functions
KR102170533B1 (ko) 암 면역요법을 위한 cd33 특이적 키메라 항원 수용체들
EP2893004B1 (en) Multi-chain chimeric antigen receptor and uses thereof
AU2015367317A1 (en) Inhibitory chimeric antigen receptor (iCAR or N-CAR) expressing non-T cell transduction domain
CN115058395A (zh) 嵌合抗原受体(car)、组合物及其使用方法
JP2020519267A (ja) より安全な細胞免疫療法のためのプロテアーゼベースの切り替えキメラ抗原受容体
RU2775453C2 (ru) Сконструированные универсальные иммунные клетки с анти-cd22 химерным антигенным рецептором
HK40071469A (en) Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy
Zhu Next Generation Receptors for the Enhanced Control of Cell-based Immunotherapies
WO2026102195A1 (en) Chimeric tcr constructs targeting bcma and cd19 or cd20 and cd19, and uses of the same
HK40001542A (en) Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy
HK40001542B (en) Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy
TW201920250A (zh) 用於以基因方式修飾且擴展淋巴球以及調節其活性之方法及組合物
HK1208879B (en) Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy
HK1212728B (en) Multi-chain chimeric antigen receptor and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160818

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161012

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171130

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171130

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181031

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190115

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190507

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190805

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191016

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200205

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200617